RT Journal Article
T1 Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.
A1 Berenguer, Juan
A1 Jarrín, Inmaculada
A1 Pérez-Latorre, Leire
A1 Hontañón, Víctor
A1 Vivancos, María J
A1 Navarro, Jordi
A1 Téllez, María J
A1 Guardiola, Josep M
A1 Iribarren, José A
A1 Rivero-Juárez, Antonio
A1 Márquez, Manuel
A1 Artero, Arturo
A1 Morano, Luis
A1 Santos, Ignacio
A1 Moreno, Javier
A1 Fariñas, María C
A1 Galindo, María J
A1 Hernando, María A
A1 Montero, Marta
A1 Cifuentes, Carmen
A1 Domingo, Pere
A1 Sanz, José
A1 Domíngez, Lourdes
A1 Ferrero, Oscar L
A1 De la Fuente, Belén
A1 Rodríguez, Carmen
A1 Reus, Sergio
A1 Hernández-Quero, José
A1 Gaspar, Gabriel
A1 Pérez-Martínez, Laura
A1 García, Coral
A1 Force, Lluis
A1 Veloso, Sergio
A1 Losa, Juan E
A1 Vilaró, Josep
A1 Bernal, Enrique
A1 Arponen, Sari
A1 Ortí, Amat J
A1 Chocarro, Ángel
A1 Teira, Ramón
A1 Alonso, Gerardo
A1 Silvariño, Rafael
A1 Vegas, Ana
A1 Geijo, Paloma
A1 Bisbe, Josep
A1 Esteban, Herminia
A1 González-García, Juan
A1 GeSIDA 8514 Study Group, 
K1 HIV infection/*epidemiology
K1 Spain/epidemiology
K1 coinfection/*epidemiology
K1 hepatitis C/drug therapy/*epidemiology
AB We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend  Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
SN 2328-8957
YR 2018
FD 2018-01-12
LK https://hdl.handle.net/10668/26398
UL https://hdl.handle.net/10668/26398
LA en
DS RISalud
RD Apr 6, 2025